These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 31713232)
41. Intravenous topiramate for seizure emergencies - First in human case report. Apostolakopoulou L; Bosque Varela P; Rossini F; O'Sullivan C; Löscher W; Kuchukhidze G; Trinka E Epilepsy Behav; 2023 May; 142():109158. PubMed ID: 37058860 [TBL] [Abstract][Full Text] [Related]
42. Treatment of pediatric refractory status epilepticus with topiramate. Akyildiz BN; Kumandaş S Childs Nerv Syst; 2011 Sep; 27(9):1425-30. PubMed ID: 21442269 [TBL] [Abstract][Full Text] [Related]
43. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Marson AG; Appleton R; Baker GA; Chadwick DW; Doughty J; Eaton B; Gamble C; Jacoby A; Shackley P; Smith DF; Tudur-Smith C; Vanoli A; Williamson PR Health Technol Assess; 2007 Oct; 11(37):iii-iv, ix-x, 1-134. PubMed ID: 17903391 [TBL] [Abstract][Full Text] [Related]
44. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Korean Topiramate Study Group. Epilepsia; 1999 Dec; 40(12):1767-74. PubMed ID: 10612342 [TBL] [Abstract][Full Text] [Related]
45. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled Phase III randomized, double-blind trials: A post-hoc analysis. Benbadis S; Klein P; Schiemann J; Diaz A; Elmoufti S; Whitesides J Epilepsy Behav; 2018 Mar; 80():129-134. PubMed ID: 29414542 [TBL] [Abstract][Full Text] [Related]
46. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Ben-Menachem E; Henriksen O; Dam M; Mikkelsen M; Schmidt D; Reid S; Reife R; Kramer L; Pledger G; Karim R Epilepsia; 1996 Jun; 37(6):539-43. PubMed ID: 8641230 [TBL] [Abstract][Full Text] [Related]
47. Status epilepticus: Refractory and super-refractory. Dubey D; Kalita J; Misra UK Neurol India; 2017; 65(Supplement):S12-S17. PubMed ID: 28281491 [TBL] [Abstract][Full Text] [Related]
48. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Ramsay E; Faught E; Krumholz A; Naritoku D; Privitera M; Schwarzman L; Mao L; Wiegand F; Hulihan J; Epilepsia; 2010 Oct; 51(10):1970-7. PubMed ID: 20633037 [TBL] [Abstract][Full Text] [Related]
49. The Unease When Using Anesthetics for Treatment-Refractory Status Epilepticus: Still Far Too Many Questions. Opić P; Sutter R J Clin Neurophysiol; 2020 Sep; 37(5):399-405. PubMed ID: 32890061 [TBL] [Abstract][Full Text] [Related]
50. Usefulness of extended-release topiramate in patients with epilepsy: A two-year retention study. Lee H; Kim DW J Clin Pharm Ther; 2021 Oct; 46(5):1412-1417. PubMed ID: 34146432 [TBL] [Abstract][Full Text] [Related]
51. Refractory and super-refractory status epilepticus in children and adolescents: A population-based study. Hepsø SW; Lee M; Noszka K; Wollertsen YM; Holmaas G; Kristensen E; Eichele T; Bjork MH; Griffiths ST; Hikmat O Seizure; 2024 Aug; 120():116-123. PubMed ID: 38941802 [TBL] [Abstract][Full Text] [Related]
52. [Efficacy and tolerability of topiramate, lamotrigine, and levetiracetam in children with refractory epilepsy]. Kato T; Nakata M; Ide M; Saito K; Yoshida T; Awaya T; Heike T No To Hattatsu; 2015 Sep; 47(5):354-9. PubMed ID: 26502652 [TBL] [Abstract][Full Text] [Related]
53. Predictors of outcomes and refractoriness in status epilepticus: A prospective study. Atmaca MM; Bebek N; Baykan B; Gökyiğit A; Gürses C Epilepsy Behav; 2017 Oct; 75():158-164. PubMed ID: 28866335 [TBL] [Abstract][Full Text] [Related]
54. Incidence and mortality of super-refractory status epilepticus in adults. Kantanen AM; Reinikainen M; Parviainen I; Ruokonen E; Ala-Peijari M; Bäcklund T; Koskenkari J; Laitio R; Kälviäinen R Epilepsy Behav; 2015 Aug; 49():131-4. PubMed ID: 26141934 [TBL] [Abstract][Full Text] [Related]
56. Costs, length of stay, and mortality of super-refractory status epilepticus: A population-based study from Germany. Strzelczyk A; Ansorge S; Hapfelmeier J; Bonthapally V; Erder MH; Rosenow F Epilepsia; 2017 Sep; 58(9):1533-1541. PubMed ID: 28681418 [TBL] [Abstract][Full Text] [Related]
58. Changes in cognition after introduction or withdrawal of zonisamide versus topiramate in epilepsy patients: A retrospective study using Bayes statistics. Meschede C; Witt JA; Brömling S; Moskau-Hartmann S; Rademacher M; Surges R; von Wrede R; Helmstaedter C Epilepsia; 2020 Jul; 61(7):1481-1490. PubMed ID: 32557579 [TBL] [Abstract][Full Text] [Related]
59. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. Holtkamp M; Othman J; Buchheim K; Meierkord H J Neurol Neurosurg Psychiatry; 2005 Apr; 76(4):534-9. PubMed ID: 15774441 [TBL] [Abstract][Full Text] [Related]
60. Topiramate in patients with learning disability and refractory epilepsy. Kelly K; Stephen LJ; Sills GJ; Brodie MJ Epilepsia; 2002 Apr; 43(4):399-402. PubMed ID: 11952770 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]